[go: up one dir, main page]

BR112023022890A2 - Inibidores de cromenona alostéricos de fosfoinositídio 3-cinase (pi3k), composições farmacêuticas que os compreendem e usos dos mesmos - Google Patents

Inibidores de cromenona alostéricos de fosfoinositídio 3-cinase (pi3k), composições farmacêuticas que os compreendem e usos dos mesmos

Info

Publication number
BR112023022890A2
BR112023022890A2 BR112023022890A BR112023022890A BR112023022890A2 BR 112023022890 A2 BR112023022890 A2 BR 112023022890A2 BR 112023022890 A BR112023022890 A BR 112023022890A BR 112023022890 A BR112023022890 A BR 112023022890A BR 112023022890 A2 BR112023022890 A2 BR 112023022890A2
Authority
BR
Brazil
Prior art keywords
pi3k
chromenone
phosphoinositide
allosteric
kinase
Prior art date
Application number
BR112023022890A
Other languages
English (en)
Inventor
Glenn Mayne Christopher
A Kesicki Edward
Danielle Anderson Erin
R Hickey Eugene
R Kolakowski Gabrielle
Maria Pototschnig Gerit
hua-yu Wang
Lynn Knight Jennifer
Alexander Mclean Johnathan
Frances Long Katelyn
Manoj Kumar
Brian Welch Michael
A Boyles Nicholas
Douglas Aronow Sean
Surendra Dawadi
Combs Irvin Thomas
Tien Widjaja
Xiaohong Chen
Original Assignee
Petra Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Petra Pharma Corp filed Critical Petra Pharma Corp
Publication of BR112023022890A2 publication Critical patent/BR112023022890A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

inibidores de cromenona alostéricos de fosfoinositídio 3-cinase (pi3k), composições farmacêuticas que os compreendem e usos dos mesmos. a presente invenção refere-se a compostos de fórmula (i) como inibidores de cromenona alostéricos de fosfoinositida 3-cinase (pi3k) úteis no tratamento de doenças ou distúrbios associados com modulação de pi3k, fórmula (i): ou sais farmaceuticamente aceitáveis dos mesmos em que r, r1, r2, r3, r4, r5, r6, r7, e r8, são como definidos neste documento. a invenção também se refere a métodos de preparar e usar compostos de fórmula (i) ou sais farmaceuticamente aceitáveis dos mesmos.
BR112023022890A 2021-05-27 2022-05-26 Inibidores de cromenona alostéricos de fosfoinositídio 3-cinase (pi3k), composições farmacêuticas que os compreendem e usos dos mesmos BR112023022890A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163193917P 2021-05-27 2021-05-27
US202163227493P 2021-07-30 2021-07-30
US202163250592P 2021-09-30 2021-09-30
US202163253352P 2021-10-07 2021-10-07
PCT/US2022/031112 WO2022251482A1 (en) 2021-05-27 2022-05-26 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112023022890A2 true BR112023022890A2 (pt) 2024-01-23

Family

ID=82258583

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022890A BR112023022890A2 (pt) 2021-05-27 2022-05-26 Inibidores de cromenona alostéricos de fosfoinositídio 3-cinase (pi3k), composições farmacêuticas que os compreendem e usos dos mesmos

Country Status (12)

Country Link
US (1) US11878970B2 (pt)
EP (1) EP4347040A1 (pt)
JP (1) JP7702057B2 (pt)
KR (1) KR20240014065A (pt)
AU (1) AU2022282380A1 (pt)
BR (1) BR112023022890A2 (pt)
CA (1) CA3219925A1 (pt)
IL (1) IL308776A (pt)
MX (1) MX2023013987A (pt)
SA (1) SA523451700B1 (pt)
TW (1) TWI829179B (pt)
WO (1) WO2022251482A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022268900B2 (en) 2021-05-03 2024-12-19 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
US20250136568A1 (en) * 2021-12-08 2025-05-01 Nanjing Zenshine Pharmaceuticals Co., Ltd. Fused heterocyclic compounds as pi3kalpha inhibitors
CN117362281A (zh) * 2022-07-07 2024-01-09 海创药业股份有限公司 一种pi3k抑制剂及其制备方法和用途
TW202432134A (zh) 2022-11-02 2024-08-16 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇３－激酶（ｐ１３ｋ）之靶向別位及正位袋點
WO2024233256A1 (en) 2023-05-05 2024-11-14 Eli Lilly And Company Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer
WO2024260464A1 (en) * 2023-06-21 2024-12-26 Regor Pharmaceuticals, Inc. Pi3k inhibitors and use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1190405B (it) 1985-10-22 1988-02-16 Recordati Chem Pharm Derivati del flavone
IL89840A (en) 1988-04-06 1996-10-31 Lipha Substituted flavonoid compounds and salts thereof their preparation and pharmaceutical composition containing them
JPH04502322A (ja) 1988-12-21 1992-04-23 ジ・アップジョン・カンパニー 抗アテローム性動脈硬化症性および抗血栓性１―ベンゾピラン―４―オン類および２―アミノ―１，３―ベンゾオキサジン―４―オン類
AU2001230426C1 (en) 2000-01-24 2006-06-22 Astrazeneca Ab Therapeutic morpholino-substituted compounds
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
US7884127B2 (en) 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
CA2495661C (en) * 2002-08-16 2011-06-14 Kinacia Pty Ltd. Inhibition of phosphoinositide 3-kinase beta
RU2010133715A (ru) 2008-01-25 2012-02-27 Астразенека Аб (Se) ЭНАНТИОМЕРНО ЧИСТАЯ (-)2-[1-(7-МЕТИЛ-2-(МОРФОЛИН-4-ИЛ)-4-ОКСО-4Н-ПИРИДО[1,2-a]ПИРИМИДИН-9-ИЛ)БЕНЗОЙНАЯ КИСЛОТА, ЕЕ ПРИМЕНЕНИЕ В ФАРМАКОТЕРАПИИ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЕЕ
EP2307414A4 (en) 2008-07-07 2011-10-26 Xcovery Holding Co Llc SELECTIVE INHIBITORS OF PI3 KINASE ISOFORMS
MX2011003372A (es) 2008-09-29 2011-06-09 Sirtris Pharmaceuticals Inc Analogos de cromenona como modulares de sirtuina.
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
CA3017366A1 (en) 2016-03-11 2017-09-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Icariin and icaritin derivatives
CN108299365B (zh) 2018-01-31 2021-08-06 中南大学 一种黄酮衍生物及其应用
AR121719A1 (es) * 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
EP4149477A4 (en) 2020-05-14 2024-04-03 The Heart Research Institute Ltd TREATMENT OF THROMBOSIS AND RELATED DISEASES WITH AN ANTI-PLATELET AGENT
US20240166617A1 (en) 2021-02-01 2024-05-23 Geode Therapeutics Inc. Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof
KR20240004744A (ko) 2021-05-03 2024-01-11 페트라 파마 코포레이션 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제
AU2022268900B2 (en) 2021-05-03 2024-12-19 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
US20250084048A1 (en) 2021-10-07 2025-03-13 Relay Therapeutics, Inc. Pi3k-alpha inhibitors and methods of use thereof
TW202334137A (zh) 2021-11-03 2023-09-01 美商薩諾管理公司 Ｐｉ３ｋ抑制劑及治療癌症之方法
WO2023078401A1 (en) 2021-11-05 2023-05-11 Fochon Biosciences, Ltd. Compounds as protein kinase inhibitors
US20250136568A1 (en) 2021-12-08 2025-05-01 Nanjing Zenshine Pharmaceuticals Co., Ltd. Fused heterocyclic compounds as pi3kalpha inhibitors

Also Published As

Publication number Publication date
EP4347040A1 (en) 2024-04-10
KR20240014065A (ko) 2024-01-31
WO2022251482A1 (en) 2022-12-01
IL308776A (en) 2024-01-01
US20230096175A1 (en) 2023-03-30
JP2024520417A (ja) 2024-05-24
SA523451700B1 (ar) 2024-10-02
TW202313605A (zh) 2023-04-01
JP7702057B2 (ja) 2025-07-03
CA3219925A1 (en) 2022-12-01
AU2022282380A1 (en) 2023-12-07
MX2023013987A (es) 2024-02-12
US11878970B2 (en) 2024-01-23
TWI829179B (zh) 2024-01-11

Similar Documents

Publication Publication Date Title
BR112023022890A2 (pt) Inibidores de cromenona alostéricos de fosfoinositídio 3-cinase (pi3k), composições farmacêuticas que os compreendem e usos dos mesmos
BR112023022940A2 (pt) Inibidores alostéricos de cromenona de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doenças
BR112023022580A2 (pt) Inibidores alostéricos de cromenona de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doenças
CO2022014160A2 (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con la modulación de p13k
MX2024003721A (es) Inhibidores alostericos de cromenona de la fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades.
BR112022010924A2 (pt) Tetra-hidrofuranos substituídos como moduladores de canais de sódio
BR112022013593A2 (pt) Inibidores de mek e usos terapêuticos dos mesmos
BR112013026345A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
BR112022021962A2 (pt) Imidazopiridazinas como moduladores de il-17
BRPI0912294B8 (pt) compostos de triazina que inibem p13 quinase e mtor, e composições farmacêuticas dos mesmos
BR112012022125A2 (pt) composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
BR112014008686A2 (pt) derivados de oxazina e uso dos mesmos no tratamento de doença
EA201490491A1 (ru) Производные 2-амино-4-(пиридин-2-ил)-5,6-дигидро-4h-1,3-оксазинов и их использование в качестве ингибиторов bace-1 и/или bace-2
BRPI0807346B8 (pt) derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)carbaldeído como inibidores de pkc, seu uso e composição farmacêutica que os compreende
BR112022023983A2 (pt) Compostos terapêuticos
BR112022024045A2 (pt) Moduladores il-17a
BR112022001067A2 (pt) Inibidores duplos de atm e dna-pk para uso em terapia antitumoral
BR112019004248A2 (pt) inibidores da dopamina-b-hidroxilase
BR112021006319A2 (pt) compostos de indolinona para uso como inibidores de map4k1
BR112023016970A2 (pt) Compostos heterocíclicos antivirais
BR112022007680A2 (pt) Derivados de n-(heteroaril)quinazolin-2-amina como inibidores de lrrk2, composições farmacêuticas, e usos dos mesmos
BR112023002082A2 (pt) Síntese de derivados de imipridona e sua avaliação para sua atividade anticancerígena
ECSP24007193A (es) Compuestos pirimidínicos para usar como inhibidores de map4k1
BR112023017626A2 (pt) Derivados de diazepina úteis no tratamento de clostridium dificile
BR112023025850A2 (pt) Inibidores da nicotinamida ripk1